Atul Dandekar, CSBO at Maze Therapeutics, Inc. (MAZE), sold 144,900 shares at $41.13 ($5.9M) on 2025-12-29, disclosed to the SEC on 2025-12-31.
Scheduled sale ($5.9M) by CSBO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.51 | 66,365 | $2.7M | 45.7% |
| 2 | $40.51 | 66,365 | $2.7M | 45.7% |
| 3 | $41.13 | 6,035 | $248K | 4.2% |
| 4 | $41.13 | 6,035 | $248K | 4.2% |
| 5 | $40.36 | 100 | $4K | 0.1% |
| Total | $40.56 avg | 144,900 |
| $5.9M |
| 100% |
| Filing → |
| MAZE | SELL | 2026-08-31 | $207K | — | Filing → |
| MAZE | SELL | 2026-07-31 | $205K | — | Filing → |
| MAZE | SELL | 2026-07-01 | $210K | — | Filing → |